This page shows the latest Cephalon news and features for those working in and with pharma, biotech and healthcare.
Two other investigations - involving AstraZeneca/Nycomed and Teva/Cephalon - did not result in enforcement action by the Commission.
In July both AstraZeneca (AZ) and Cephalon settled an action brought by the US government which accused them of underpaying. ... AZ paid nearly $47m to settle the cases, with Cephalon stumping up $7.5m, and at the time the DoJ said it would "continue to
Israeli-based Teva has reached a settlement resolving the Commission's antitrust suit charging its subsidiary Cephalon, with illegally blocking generic competition to its blockbuster sleep-disorder drug Provigil (modafinil). ... As part of the settlement,
Teva is paying $512m to settle a legal case against its subsidiary Cephalon used pay-for-delay tactics on its wakefulness drug Provigil (modafinil). ... cases. The lawsuit, originally filed in 2006 by drug wholesalers and retailers that buy directly from
Meanwhile, antitrust investigators in the EU are still looking at possible collusion between Teva and Cephalon, which is now owned by the Israeli company, concerning narcolepsy treatment Provigil (modafinil), while a
Biosimilar companies can reduce their market access time by linking with other companies with expertise in biosimilars manufacturing and development, Sashidhar added, citing Teva's alliance with Cephalon and Lupin Pharmaceuticals'
More from news
Approximately 1 fully matching, plus 68 partially matching documents found.
This has proved to be the case following Teva's purchase of Cephalon in May 2011 for $6.2bn which brought Provigil (modafinil for sleep disorders) into the portfolio.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Prior to her time with Pfizer, Barrett held roles with Cephalon andchief executive officer at Novartis, said: “Liz is a highly accomplished and recognised oncology and people leader with an impressive
His career to date has seen him hold positions such as head of business development, global branded products at Teva Pharmaceuticals, VP of business development and strategic planning at Cephalon and
Prior to this he worked at Teva as senior vice president and head of global clinical development following that company's acquisition of Cephalon, where he was senior vice president, worldwide
of Cephalon and chief financial officer of Centocor.
His career includes senior managed roles at Cephalon and a senior VP position at SmithKline Beecham Pharmaceuticals, now GSK.
More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.
Arsenic. Trisenox. Cephalon. Treatment of patients with. acute promyelocytic leukaemia. .
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...